E-mail

E-mail a Wiley Online Library Link

Jeffrey Peppercorn, Erika Hamilton, Paul Kelly Marcom, Laura Beskow and Gary H. Lyman Pharmacogenetic testing in the face of unclear clinical efficacy: Lessons from cytochrome P450 2D6 for tamoxifen Cancer 119

Version of Record online: 24 JUL 2013 | DOI: 10.1002/cncr.28263

Prior to definitive evidence, a minority of oncologists reported using the cytochrome P450 2D6 (CYP2D6) test routinely, and many indicated willingness to change management of patients based on test results. There is a clear need to educate clinicians and the public regarding the uncertain benefits of commercially available genetic tests in clinical practice when evidence from ongoing trials is still emerging.

Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf

Required = Required Field

SEARCH